Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • Persone
  • Pubblicazioni
  • Facoltà
  • Ambiti Di Ricerca

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • Persone
  • Pubblicazioni
  • Facoltà
  • Ambiti Di Ricerca
  1. Pubblicazioni

Three-Year Durability of Automated Insulin Delivery Therapy in Children and Adolescents with Type 1 Diabetes: A Multicenter Real-World Study

Articolo
Data di Pubblicazione:
2026
Citazione:
Three-Year Durability of Automated Insulin Delivery Therapy in Children and Adolescents with Type 1 Diabetes: A Multicenter Real-World Study / Bombaci, B., Lombardo, F., Bassi, M., Minuto, N., Tornese, G., Catamo, E., Bonfanti, R., Rigamonti, A., Reinstadler, P., Kalapurackal, M.A., Mameli, C., Zuccotti, G., Maffeis, C., Piona, C., Delvecchio, M., Arnaldi, C., Felappi, B., Mozzillo, E., Roppolo, R., Maltoni, G., et al.. - In: DIABETES TECHNOLOGY & THERAPEUTICS. - ISSN 1520-9156. - (2026). [10.1177/15209156261469663]
Abstract:
Introduction: Evidence on the long-term durability of glycemic control beyond the first year of automated insulin delivery therapy remains limited, particularly in large multicenter pediatric cohorts. The present study aimed to evaluate long-term effectiveness and identify determinants of sustained optimal outcomes over 3 years of MiniMed™ 780G use in youth with type 1 diabetes (T1D). Materials and Methods: In this longitudinal, multicenter, real-world study, 359 youth with T1D (median age 12.2 years, 50.9% female) from 20 Italian pediatric diabetes centers were followed for 3 years after MiniMed 780G initiation. Glucose metrics, insulin delivery parameters, device settings, and engagement indicators were analyzed at 1, 2, and 3 years. Longitudinal changes were assessed using linear mixed-effects models. Multivariable logistic regression identified predictors of achieving time in tight range target (TITR ≥ 50%) at 3 years. Results: Median time in range (TIR) remained within international targets but declined modestly from 75% at 1 year to 74% at 3 years (P = 0.002). The percentage of automatic correction boluses increased over time, whereas user-initiated boluses and carbohydrate entries declined (P < 0.001). Youth with higher TIR at 1 year showed a progressive reduction in TIR and greater increase in automated corrections (time × group interaction P < 0.001). At 3 years, higher SmartGuard use (odds ratio [OR]: 1.13, 95% confidence interval [CI]: 1.03–1.23; P = 0.007), optimal system settings (OR: 3.21, 95% CI: 1.33–7.77; P = 0.010), and lower automatic correction boluses (OR: 0.84, 95% CI: 0.80–0.89; P < 0.001) were independently associated with achieving TITR ≥50%. Conclusions: MiniMed 780G provides sustained glycemic control over 3 years. However, progressive reliance on automated corrections and reduced user engagement may attenuate tight glycemic control, highlighting the need for ongoing education and proactive device optimization.
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Bombaci, B.; Lombardo, F.; Bassi, M.; Minuto, N.; Tornese, G.; Catamo, E.; Bonfanti, R.; Rigamonti, A.; Reinstadler, P.; Kalapurackal, M. A.; Mameli, C.; Zuccotti, G.; Maffeis, C.; Piona, C.; Delvecchio, M.; Arnaldi, C.; Felappi, B.; Mozzillo, E.; Roppolo, R.; Maltoni, G.; Lo Presti, D.; Pezzino, G.; Zanfardino, A.; Salzano, G.; Passanisi, S.
Autori di Ateneo:
BONFANTI RICCARDO
Link alla scheda completa:
https://iris.unisr.it/handle/20.500.11768/206676
Pubblicato in:
DIABETES TECHNOLOGY & THERAPEUTICS
Journal
  • Dati Generali

Dati Generali

URL

https://journals.sagepub.com/doi/10.1177/15209156261469663
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.9.2.0